HHS
Harte Hanks, Inc.
There isn't enough reported data to score HHS yet.
TMUS
T-Mobile US, Inc.
TMUS's fundamentals are mixed, but it looks cheap: trading at 16x earnings, below its usual 27x. Analysts expect strong earnings growth.
HHS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Strong |
HHS's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
TMUS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Strong | |
| Strong |
TMUS's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
HHS PE Valuation
HHS has no meaningful PE right now: it lost money over the past year.
TMUS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 13x | $171 | — |
| Current | 16x | $171 | — |
| Cheap | 21x | $218 | +27% |
| Fair | 26x | $274 | +60% |
| Expensive | 56x | $581 | +240% |
Historical ranges are pointers, not guarantees.
TMUS's PE is in its cheap range at 16x. If earnings grow as analysts expect, today's price would be 13x next year's earnings.
HHS Forward outlook
There aren't enough analyst estimates for HHS to show an outlook.
TMUS Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for TMUS, with profitability improving.
HHS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.76 | -$0.37 |
| Q1 2026 | -$0.14 | +$4.04 |
| Q4 2025 | -$0.11 | +$4.04 |
| Q3 2025 | -$0.72 | +$3.38 |
| Q2 2025 | -$0.39 | +$3.65 |
| Q1 2025 | -$4.18 | -$4.06 |
| Q4 2024 | -$4.15 | -$3.94 |
| Q3 2024 | -$4.10 | -234% |
HHS is still losing money, but far less than before: $0.76 per share over the past year, against $4.27 at its worst in late 2019.
TMUS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.49 | +30% |
| Q3 2026 | $10.37 | -0.2% |
| Q2 2026 | $9.56 | -9.7% |
| Q1 2026 | $9.41 | -8.1% |
| Q4 2025 | $9.72 | +0.6% |
| Q3 2025 | $10.39 | +18% |
| Q2 2025 | $10.59 | +33% |
| Q1 2025 | $10.24 | +39% |
| Q4 2024 | $9.66 | +39% |
TMUS has the edge over HHS on earnings quality, reporting a profit while its opponent remains loss making.
HHS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $38M | -1.7% |
| Q1 2026 | $37.3M | -10% |
| Q4 2025 | $39.9M | -15% |
| Q3 2025 | $39.5M | -17% |
| Q2 2025 | $38.6M | -14% |
| Q1 2025 | $41.6M | -8.6% |
| Q4 2024 | $47.1M | -4.8% |
| Q3 2024 | $47.6M | +1.1% |
HHS's revenue has slid since its 2022 peak: $38M last quarter, down 1.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -12% | -12 points |
| Q1 2026 | -2.1% | -2 points |
| Q4 2025 | -0.3% | +3 points |
| Q3 2025 | 1.3% | -2.7 points |
| Q2 2025 | 0.1% | -3 points |
| Q1 2025 | -0.1% | -0.9 points |
| Q4 2024 | -3.3% | +1.3 points |
| Q3 2024 | 4% | -2.2 points |
HHS's operating margin was −12% last quarter, down 12 points from the same quarter a year ago, near the bottom of its range since 2019.
TMUS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $23.6B | +7.4% |
| Q2 2026 | $22.8B | +7.9% |
| Q1 2026 | $23.1B | +11% |
| Q4 2025 | $24.3B | +11% |
| Q3 2025 | $22B | +8.9% |
| Q2 2025 | $21.1B | +6.9% |
| Q1 2025 | $20.9B | +6.6% |
| Q4 2024 | $21.9B | +6.8% |
TMUS has the edge over HHS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 24% | +3.4 points |
| Q2 2026 | 24% | -0.6 points |
| Q1 2026 | 19% | -3.5 points |
| Q4 2025 | 15% | -5.6 points |
| Q3 2025 | 21% | -3.2 points |
| Q2 2025 | 25% | +1.3 points |
| Q1 2025 | 23% | +2.6 points |
| Q4 2024 | 21% | +4 points |
TMUS has the edge over HHS on profitability, with a higher operating margin.
HHS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2M | +$3M |
| Q1 2026 | -$922K | +$1K |
| Q4 2025 | -$686K | -120% |
| Q3 2025 | $2.2M | +$7M |
| Q2 2025 | -$5.1M | -648% |
| Q1 2025 | -$923K | +$5.3M |
| Q4 2024 | $3.4M | +13% |
| Q3 2024 | -$4.9M | -474% |
HHS has burned cash in six of the last eight quarters: −$1M over the past year, against −$7M the year before.
TMUS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +5.3% |
| Q2 2026 | $4.8B | +4.4% |
| Q1 2026 | $4.6B | +4.6% |
| Q4 2025 | $4.2B | +25% |
| Q3 2025 | $4.8B | +15% |
| Q2 2025 | $4.6B | +32% |
| Q1 2025 | $4.4B | +79% |
| Q4 2024 | $3.3B | +2% |
TMUS has the edge over HHS on cash generation, producing positive trailing cash flow while its opponent burns cash.
HHS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +15K shares |
| 1 year | +0.7% | +49K shares |
| 3 years | -1% | -74K shares |
| 5 years | +3.3% | +238K shares |
| Available history | +18% | +1.1M shares |
HHS has 7M diluted shares, up 0.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q4 2023 | — |
| Q3 2023 | $491,000 |
TMUS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -10.8M shares |
| 1 year | -4.9% | -55M shares |
| 3 years | -8.8% | -103M shares |
| 5 years | -15% | -182M shares |
| Available history | +24% | +207M shares |
TMUS has the edge over HHS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $2.4B |
| Q2 2026 | $2.3B |
| Q1 2026 | $4.8B |
| Q4 2025 | $2.4B |
| Q3 2025 | $2.5B |
| Q2 2025 | $2.6B |
| Q1 2025 | $2.5B |
| Q4 2024 | $4.7B |
TMUS spent $12B buying back its own shares over the past year, down 1.7% from the year before.
HHS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -1.1x | Net Cash |
| Q4 2025 | -1.2x | Net Cash |
| Q3 2025 | -1.8x | Net Cash |
| Q2 2025 | -1.0x | Net Cash |
| Q1 2025 | -1.5x | Net Cash |
| Q4 2024 | -1.5x | Net Cash |
| Q3 2024 | -1.1x | Net Cash |
| Q2 2024 | -1.7x | Net Cash |
HHS has more cash than debt.
TMUS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.0x | Very low |
| Q2 2026 | 0.1x | Very low |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | 2.5x | Moderate |
| Q3 2025 | 0.1x | Very low |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | 2.4x | Moderate |
TMUS's net debt is less than a year of its operating earnings (EBITDA).
HHS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.1 | Neutral |
| Stochastic | 72.7 | Neutral |
HHS's weekly RSI is 57 (neutral) and its Stochastic is 73 (neutral).
TMUS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.9 | Neutral |
| Stochastic | 42.1 | Neutral |
TMUS's weekly RSI is 48 (neutral) and its Stochastic is 42 (neutral).
HHS PE vs Communication Services Sector
| Metric | HHS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 16x | — |
HHS has no meaningful PE right now: it lost money over the past year.
TMUS PE vs Communication Services Sector
| Metric | TMUS | Sector median | Relative |
|---|---|---|---|
| PE | 16x | 16x | Same PE |
| PE % | 1 | 26 | 25 pts below |
TMUS is trading at 16x earnings, in line with the Communication Services sector's median of 16x.
HHS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.21 | 4.3% below |
| 20 week MA | $3.66 | 10% above |
| 50 week MA | $3.14 | 28% above |
| 100 week MA | $3.70 | 8.9% above |
| 200 week MA | $5.54 | 27% below |
HHS has the edge over TMUS on trend strength, trading above more of its moving averages.
TMUS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $159.1 | 7.5% above |
| 20 week MA | $172.0 | 0.5% below |
| 50 week MA | $187.8 | 8.9% below |
| 100 week MA | $212.9 | 20% below |
| 200 week MA | $188.7 | 9.4% below |
TMUS has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 9.4% below its 200-week average.
HHS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3.46 | $2.55 | -26% |
| 2021 | $2.55 | $8.17 | +220% |
| 2022 | $8.17 | $11.5 | +41% |
| 2023 | $11.5 | $6.79 | -41% |
| 2024 | $6.79 | $5.38 | -21% |
| 2025 | $5.38 | $3.32 | -38% |
| 2026 YTD | $3.32 | $4.03 | +21% |
HHS has the edge over TMUS on returns for 2026, with the stronger performance.
TMUS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $77.2 | $132.9 | +72% |
| 2021 | $132.9 | $119.9 | -9.8% |
| 2022 | $119.9 | $140.0 | +17% |
| 2023 | $140.0 | $160.3 | +15% |
| 2024 | $160.3 | $223.0 | +39% |
| 2025 | $223.0 | $201.0 | -9.9% |
| 2026 YTD | $201.0 | $171.0 | -15% |
TMUS has finished higher in four of the last six years. It's down 15% so far in 2026.